P174 MAGNESIUM IMPROVES METABOLIC PROFILE AND HYPERTENSION

Background and Objective: Magnesium is an essential electrolyte involved in about 600 enzymatic reactions and metabolic processes. Recent data show that nutritive magnesium supplementation decreases interleukin-6 levels and metabolic parameters. Patients and Methods: We conducted a prospective double-blinded, prospective study on magnesium and interleukin-6 and blood pressure values in 27 patients with a metabolic syndrome as compared to 27 controls (all patients beyond 60 years with normal renal function). Patients were supplemented with 400 mg magnesium daily. Measurements of parameters were performed before and after 6 and 12 weeks of treatment. Results: In the magnesium-treated group, interleukin-6 values decreased significantly from 4.94+/-3.30 to 4.53+/-6.89 after 6 weeks to 3.01+/-1.32pg/mL after 12 weeks (mean+/-SD, p < 0.01). In the control group, interleukin-6 was 3.73+/-4.36 before the start of supplementation, 4.87+/-4.35 after 6 weeks, and 4.41+/- 3,15 pg/mL after 12 weeks (n.s.). In the magnesium-treated group, there was also a significant decrease in both systolic and diastolic blood pressure after 12 weeks (systolic: 134.6+/-6.8 to 126.3+/-5.6 mmHG; diastolic: 84.1+/-3.9 to 79.4+/-1.6 mmHg)(mean+/-SD, p< 0.01). HbA1c and lipd profile increased in patients slightly not reaching significane. Vitamin D status also improved significantly in patients after 12 weeks (p< 0.05). For statistics Mann-Whitney U test was used. Conclusions: In patients wit metabolic syndrome, magnesium supplementation significantly decreased interleukin-6 and both systolic and diastolic blood pressure values, vitamin D significantly increased. Metabolic parameters improved. The anti-inflammatory effects of magnesium as well as anti-arteriosclerotic effects are of benefit for patients with a metabolic syndrome at a high risk for cardiovascular diseases and mortality.